Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – UZPRUVO

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Ustekinumab Testmiljö

Ustekinumab

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.

  2. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.

  3. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.

  4. Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022;44(10):1336-1355.

  5. Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z et al. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol. 2020;60(7):889-902.

  6. Stelara (ustekinumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2022-11-01, cited 2022-12-01]

  7. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960.

  8. Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A et al. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. J Gastroenterol Hepatol. 2021;36(8):2067-2075.

  9. Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N et al. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. World J Gastroenterol. 2019;25(31):4481-4492.

  10. Lorenzo González L, Valdés Delgado T, Vázquez Morón JM, Castro Laria L, Leo Carnerero E, Maldonado Pérez MB et al. Ustekinumab in Crohn's disease: real-world outcomes and predictors of response. Rev Esp Enferm Dig. 2022;114(5):272-279.

  11. Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D et al. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflamm Bowel Dis. 2019;25(4):767-774.

  12. Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2020;14(5):694-709.

  13. Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Massaro A, Egan CG et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20(1):95-104.

  14. Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185(6):1160-1168.

  15. Geale K, Lindberg I, Paulsson EC, Wennerström ECM, Tjärnlund A, Noel W et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.

  16. Oh S, Choi S, Yoon HS. Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis. Ann Dermatol. 2022;34(5):321-330.

  17. Pogácsás L, Borsi A, Takács P, Remenyik É, Kemény L, Kárpáti S et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017;28(7):635-641.

  18. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913-1920.

  19. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  20. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]

  1. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.
  2. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.
  3. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.
  4. Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022;44(10):1336-1355.
  5. Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z et al. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol. 2020;60(7):889-902.
  6. Stelara (ustekinumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2022-11-01, cited 2022-12-01]
  7. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016;375(20):1946-1960.
  8. Plevris N, Fulforth J, Siakavellas S, Robertson A, Hall R, Tyler A et al. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. J Gastroenterol Hepatol. 2021;36(8):2067-2075.
  9. Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N et al. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease. World J Gastroenterol. 2019;25(31):4481-4492.
  10. Lorenzo González L, Valdés Delgado T, Vázquez Morón JM, Castro Laria L, Leo Carnerero E, Maldonado Pérez MB et al. Ustekinumab in Crohn's disease: real-world outcomes and predictors of response. Rev Esp Enferm Dig. 2022;114(5):272-279.
  11. Weaver KN, Gregory M, Syal G, Hoversten P, Hicks SB, Patel D et al. Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflamm Bowel Dis. 2019;25(4):767-774.
  12. Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2020;14(5):694-709.
  13. Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Massaro A, Egan CG et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20(1):95-104.
  14. Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185(6):1160-1168.
  15. Geale K, Lindberg I, Paulsson EC, Wennerström ECM, Tjärnlund A, Noel W et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.
  16. Oh S, Choi S, Yoon HS. Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis. Ann Dermatol. 2022;34(5):321-330.
  17. Pogácsás L, Borsi A, Takács P, Remenyik É, Kemény L, Kárpáti S et al. Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. J Dermatolog Treat. 2017;28(7):635-641.
  18. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913-1920.
  19. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
  20. Concise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2019-03-14.]